E-6201 is under clinical development by Eisai and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect E-6201’s likelihood of approval (LoA) and phase transition for Metastatic Brain Tumor took place on 23 May 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 23 May 2022 decreased E-6201’s LoA and PTSR for Metastatic Melanoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their E-6201 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

E-6201 overview

E-6201 is under development for the treatment of brain metastasis in BRAF V600-Mutated Metastatic Melanoma. It is administered topically and intravenously. E-6201 is a small molecule and synthetic analog of a fungal metabolite. The drug candidate acts by targets FLT3 (FMS-like tyrosine kinase 3), mitogen activated protein kinase kinase 1 (MEK-1 or MAP2K1) and mitogen activated protein kinase kinase kinase (MEKK1). It was also under development for plaque-type psoriasis, acute myeloid leukemia, myelodysplastic syndrome and chronic myelomonocytic leukemia.

Eisai overview

Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Quick View E-6201 LOA Data

Report Segments
  • Innovator
Drug Name
  • E-6201
Administration Pathway
  • Intravenous
  • Topical
Therapeutic Areas
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.